|
|
J Corbeil, E Rapaport, D D Richman, D J Looney
J Clin Invest. 1994;
93(5):1981
doi:10.1172/JCI117190
Abstract |
Full text
| PDF

A
panel of retinoid compounds (tretinoin, isotretinoin, acitretin, and RO13-1470) were tested for inhibitory activity against Kaposi's sarcoma cell (KSC) cultures in vitro. Tretinoin was found to be the most effective retinoid tested, inhibiting the growth of KSC in vitro while having no effect on the expression of interleukin-6 and basic fibroblast growth factor, two important cytokines involved in KSC growth. Tretinoin also did not appear to downregulate the expression of receptors for these two cytokines. At low concentrations (10(-9) M), acitretin and tretinoin selectively inhibited growth of early passage KSC. At higher concentrations (10(-6)-10(-5) M), retinoid treatment induced a pattern of DNA degradation and morphological changes in KSC characteristic of apoptosis (programmed cell death). The inhibitory activity of tretinoin on KSC growth was decreased if human serum (but not fetal calf serum) was present in the growth medium, and partially restored by removal of serum lipids. These data suggest that retinoids possess potential as therapeutic agents in Kaposi's sarcoma.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(19)
| Title and authors |
Publication |
Year |
4-Hydroxybenzyl Modification of the Highly Teratogenic Retinoid, 4-[(1<i>E</i>)-2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-propen-1-yl]benzoic Acid (TTNPB), Yields a Compound That Induces Apoptosis in Breast Cancer Cells and Shows Reduced Teratogenicity
Allyson L. Anding, Nirca J. Nieves, Victoria V. Abzianidze, Michael D. Collins, Robert W. Curley, Margaret Clagett-Dame
|
Chem. Res. Toxicol.
|
2011 |
Sarcoma de Kaposi parte II: tratamiento
Ana De Andrés Del Rosario, Manuel Almagro Sánchez, Laura Rosende Maceiras, Eduardo Fonseca Capdevila
|
Piel
|
2011 |
Study on Preparation and Some Properties of Panretin-Loaded Nanocapsules
A. Shokuhi Ra
|
Biotechnology
|
2010 |
Neuronal Differentiation of Synovial Sarcoma and Its Therapeutic Application
Tatsuya Ishibe, Tomitaka Nakayama, Tomoki Aoyama, Takashi Nakamura, Junya Toguchida
|
Clin Orthop Relat Res
|
2008 |
Retinoid Receptors
Batya B. Davidovici, Yalçin Tüzün, Ronni Wolf
|
Dermatologic Clinics
|
2007 |
Treatments of AIDS-related Kaposi's sarcoma
A CATTELAN, L SALVAGNO, G CRIVELLARI, G BANNA, M TREVENZOLI, V CHIARIONSILENI, S MONFARDINI
|
Critical Reviews in Oncology/Hematology
|
2005 |
Novel pharmacological therapies for the treatment of AIDS-related Kaposi’s sarcoma
Anna Maria Cattelan, Marco Trevenzoli, Savina Maria Lucia Aversa
|
Expert Opin. Investig. Drugs
|
2004 |
Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms
Susan E Krown
|
Hematology/Oncology Clinics of North America
|
2003 |
Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma
Steven A. Miles, Bruce J. Dezube, Jeannette Y. Lee, Susan E. Krown, Mary Ann Fletcher, M. Wayne Saville, Lawrence Kaplan, Jerome Groopman, David T. Scadden, Timothy Cooley, Jamie Von Roenn, Alvin Friedman-Kien
|
AIDS
|
2002 |
Recent Advances in the Treatment of AIDS-Related Kaposi??s Sarcoma
Anna M. Cattelan, Marco Trevenzoli, Savina M.L. Aversa
|
American Journal of Clinical Dermatology
|
2002 |
|